<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825613</url>
  </required_header>
  <id_info>
    <org_study_id>HBPLS01</org_study_id>
    <nct_id>NCT04825613</nct_id>
  </id_info>
  <brief_title>&quot;Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis</brief_title>
  <acronym>HBPLS</acronym>
  <official_title>&quot;Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral Sclerosis&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Biosciences Stem Cell Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hope Biosciences</source>
  <brief_summary>
    <textblock>
      This Individual Patient Expanded Access IND has been created as requested by an 83-year-old&#xD;
      man who suffers Primary Lateral Sclerosis and for which the drugs currently approved are not&#xD;
      providing an improvement over the progression of this disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Individual Patient Expanded Access IND with the primary goal of treatment for an&#xD;
      individual with Primary Lateral Sclerosis. There are no FDA approved, fully restorative&#xD;
      treatments for Primary Lateral Sclerosis. The subject will receive a total of twelve&#xD;
      autologous monthly HB-adMSCs infusions of 200 million cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Temporarily not available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Primary Lateral Sclerosis, Adult, 1</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-adMSCs</intervention_name>
    <description>Hope Biosciences adipose derived Mesenchymal Stem Cells</description>
    <other_name>MSC's</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult individual at least 18 years old&#xD;
&#xD;
          2. Clinical diagnosis Primary Lateral Sclerosis.&#xD;
&#xD;
          3. Subject or Legal Authorized Representative has provided informed consent before&#xD;
             initiation of any study procedure.&#xD;
&#xD;
          4. Subject has mesenchymal stem cells banked at Hope Biosciences.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or&#xD;
             endocrine disease or any other acute or chronic medical condition that, in the opinion&#xD;
             of the principal investigator, may increase the risks associated with study&#xD;
             participation.&#xD;
&#xD;
          2. Chemical or ETOH dependency that in the opinion of the investigator would preclude&#xD;
             participation in the study.&#xD;
&#xD;
          3. Participation in concurrent interventional research studies during this expanded&#xD;
             access.&#xD;
&#xD;
          4. Unwillingness to return for follow-up visits.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hope Biosciences Stem Cell Research Foundation</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

